Therefore, comprehending the interplay between EGFR and SLC7A11 in the context of NPC, and their impact on the MHC-I antigen presentation, is vital for the development of SLC7A11-targeted therapies aimed at enhancing the immune response of CD8+T cells. The gene discussed is CD8A; the disease is nasopharyngeal carcinoma.